Clinical trialPhase 1Completed

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors

NCT04943900 ↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome: Finished, no results posted
Phase: Phase 1
Status: Completed
Study type: Interventional
Start: 9 August 2021
Expected end: 27 February 2025
Enrollment: 67 participants
Sites: 19
Primary outcomes: Incidence of Adverse Events (AEs); Incidence of Serious Adverse Events (SAEs); Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria; Incidence of AEs leading to discontinuation; Incidence of AEs leading to death
Sponsor: Industry
Results posted: No
Last update: 9 April 2025

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors.